Brainstorm Cell Therapeutics Inc. (BCLI) intrinsic value & 10-year financials
Brainstorm Cell Therapeutics Inc. (BCLI) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.78
- Market cap
- $7.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -75.1%
- Free cash flow (FY2025)
- —
BCLI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$10.3M | -$1.11 | — | — | 124.7% |
| FY2024 | — | -$11.6M | -$2.31 | — | — | 179.3% |
| FY2023 | — | -$17.2M | -$0.40 | -$20.5M | — | 520.4% |
| FY2022 | — | -$24.3M | -$0.66 | -$19.3M | — | -1627.7% |
| FY2021 | — | -$24.5M | -$0.68 | -$26.6M | — | -776.3% |
| FY2020 | — | -$31.8M | -$1.07 | -$35.6M | — | 672.6% |
| FY2019 | — | -$23.3M | — | -$11.7M | — | 613.4% |
| FY2018 | — | -$13.9M | — | -$12.8M | — | -342.4% |
| FY2017 | — | -$5.0M | — | -$2.5M | — | -63.4% |
| FY2016 | — | -$5.0M | — | -$6.0M | — | -51.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BRAINSTORM CELL THERAPEUTICS INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
BRAINSTORM CELL THERAPEUTICS INC. has historically struggled to out-earn its cost of capital, averaging just 0.2% ROIC.
BRAINSTORM CELL THERAPEUTICS INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
BRAINSTORM CELL THERAPEUTICS INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.